Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P86D | ISIN: US45790W1080 | Ticker-Symbol:
NASDAQ
23.04.25
21:59 Uhr
0,984 US-Dollar
0,000
0,00 %
1-Jahres-Chart
INOZYME PHARMA INC Chart 1 Jahr
5-Tage-Chart
INOZYME PHARMA INC 5-Tage-Chart

Aktuelle News zur INOZYME PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.04.H.C. Wainwright maintains Buy on Inozyme stock with $16 target4
10.04.Inozyme Pharma Inc.: Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency3
11.03.H.C. Wainwright maintains Buy on Inozyme stock with $16 target16
INOZYME PHARMA Aktie jetzt für 0€ handeln
10.03.Inozyme Pharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
10.03.Inozyme Pharma GAAP EPS of -$1.622
10.03.Inozyme Pharma Inc.: Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights220- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction...
► Artikel lesen
10.03.Inozyme Pharma, Inc. - 10-K, Annual Report2
10.03.Inozyme Pharma, Inc. - 8-K, Current Report4
21.02.Inozyme Pharma Inc.: Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 20257
10.01.Inozyme meldet vielversprechende Daten zu Behandlungen seltener Krankheiten26
10.01.Inozyme reports promising data on rare disease treatments4
10.01.Inozyme Pharma, Inc. - 8-K, Current Report14
05.11.24Piper Sandler raises Inozyme Pharma target to $43 from $406
05.11.24Piper Sandler erhöht Kursziel für Inozyme Pharma auf 43 US-Dollar von 40 US-Dollar6
05.11.24Inozyme Pharma Inc.: Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights191- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 - - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric...
► Artikel lesen
05.11.24Inozyme Pharma, Inc. - 10-Q, Quarterly Report1
05.11.24Inozyme Pharma, Inc. - 8-K, Current Report1
24.10.24Inozyme Pharma Inc.: Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701191- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with...
► Artikel lesen
17.10.24Inozyme Pharma Inc.: Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024158BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ("the Company" or "Inozyme"), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases...
► Artikel lesen
25.07.24Inozyme Pharma Inc.: Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function213- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT - BOSTON, July 25...
► Artikel lesen
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1